

# Standard operating procedure

## Administration of Inclisiran Injections

<b>Version:</b>	<b>Owner:</b>	<b>Created:</b>
1.0 1.1	C Talbot S. Mohamed	May 23 June 2025
<b>Published:</b>	<b>Approving Director:</b>	<b>Next Review</b>
May 2026	Kathy Ryan	May 2027

# Contents

## Introduction

Inclisiran is recommended as an option for the secondary prevention of the treatment of primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults with a history of established cardiovascular disease whose LDL cholesterol concentrations are persistently 2.6mmol/l or more despite maximum tolerated lipid-lowering therapy.

## Indication

Primary hypercholesterolaemia or mixed dyslipidaemia (in combination with a statin, or with a statin and other lipid-lowering therapies, or with other lipid-lowering therapies or alone if a statin contra-indicated or not tolerated).

<https://bnf.nice.org.uk/drug/inclisiran.html> [Accessed 18/02/2022].

No dose adjustment in patients over 65, mild or moderate hepatic impairment (use with caution in severe), or renal impairment (any stage, but use with caution in severe).

## Administration

Inclisiran may be administered by a trained nurse following recent prescription which should be visible on EMIS medications record, or a Patient Specific Direction (PSD).

Leqvio® 284 mg solution for injection in pre-filled syringe.

Inject subcutaneously into the abdomen; alternatively inject subcutaneously into the thigh or upper arm.

Initial doses 0 and 3 months, maintenance dose every 6 months.

## Missed doses

If a planned dose is missed by less than 3 months, inclisiran should be administered and dosing continued according to the patient's original schedule.

## Administration of Inclisiran Injections 1.0

If a planned dose is missed by more than 3 months, a new dosing schedule should be started – inclisiran should be administered initially, again at 3 months, followed by every 6 months.

<https://www.medicines.org.uk/emc/product/12039/smpc#gref> [Accessed 18/02/2022].

### Storage

This medicinal product does not require any special storage conditions. Do not freeze. A stock will be kept in room 7.

### Monitoring

50% reduction in LDL cholesterol concentrations should be seen 30-60 days after treatment.

Repeat full lipid profile on the same day as the 2<sup>nd</sup> dose (given at 3 months).

Patients should be booked a double appointment for the administration of the 2<sup>nd</sup> dose to allow adequate time for the blood test and administration of the inclisiran injection.

### Documentation

Problem - CVD/Dyslipidaemia/Hypercholesterolaemia.

Procedure – use code ‘subcutaneous injection’, and freetext in manufacturer, expiry date, batch number, route.

Follow-up – use ‘**lipid lowering therapy**’ code and put date when next injection due. If this is this for 2<sup>nd</sup> dose, add Ardens diary recall for repeat lipids at the same time as 2<sup>nd</sup> dose (at 3 months).

### Prescription

Nurse administering injection to add prescription to EMIS (medication, add drug, issue, approve and complete).

### Recalls

Recall code in diary - lipid lowering therapy.

CST/ SXM will run monthly lipid lowering therapy report.

### References

## Administration of Inclisiran Injections 1.0

**BNF** <https://bnf.nice.org.uk/drug/inclisiran.html> [Accessed 18/02/2022]

**EMC** <https://www.medicines.org.uk/emc/product/12039/smpc#PRODUCTINFO>  
[Accessed 18/05/2023]

**NICE** <https://www.nice.org.uk/guidance/ta733/resources/inclisiran-for-treating-primary-hypercholesterolaemia-or-mixed-dyslipidaemia-pdf-82611252825541> [Accessed 18/05/2023]

### Version Control

Date	Version	Author	Change Details
1.0	C Talbot	May 23	Created
1.1	S.Mohamed	June 2025	Updated